drugset / Trial / NCT04401995
Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab
Phase 2
Completed
9 enrolled
Diwakar Davar
CellSight Technologies, Inc. · collabCheckmate Pharmaceuticals · collab
RandomizedSequentialOpen-labelTreatment
Summary
The main goal of this research study is to determine how nivolumab and nivolumab/Vidutolimod (CMP-001) combination affect the likelihood of destroying melanoma involving lymph node and/or in-transit/satellite areas. The main goal of the PET/CT scan with 18F\]F-AraG is to evaluate how \[18F\]F-AraG uptake changes before and after administration of either nivolumab or nivolumab/CMP-001 combination.
Timeline
- Start
- 2020-09-02
- Primary completion
- 2024-08-16
- Completion
- 2024-08-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |
| Subject | Vidutolimod | Other / unclassified | 5 mg | Subcutaneous |